Revelation Biosciences Inc. to Participate in a Fireside Chat at the 35th Annual Roth Conference

Rhea-AI Impact
Rhea-AI Sentiment
(Very Negative)

SAN DIEGO--(BUSINESS WIRE)-- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic-based therapies for the prevention and treatment of disease, announced today that its Chief Executive Officer James Rolke will participate in a fireside chat at the 35th Annual Roth Conference scheduled for March 12-14, 2023 to be held at The Ritz Carlton, Laguna Niguel in Dana Point, California.

Details regarding Revelation fireside chat are as follows:

35th Annual Roth Conference Presentation Details


Tuesday, March 14, 2023


12:30 p.m. Pacific Time


Healthcare - Salon 5 @ The Ritz Carlton, Laguna Niguel


REVB Webcast Link

A live webcast of the presentation will also be available in the Investor Relations section of Revelation’s website at A replay of the presentation will be available on Revelation’s website for 30 days following the event.

Mr. Rolke will be available for one-on-one meetings throughout the conference in person and virtually.

About Revelation Biosciences Inc.

Revelation Biosciences, Inc. is a life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has multiple product candidates in development that are based on the well-established biology of phosphorylated hexaacyl disaccharide (PHAD) and its effect on the innate immune system. REVTx‑100 is being developed as a prevention and treatment of infection. REVTx‑200 is being developed as an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx‑300 is being developed as a potential therapy for the treatment of acute and chronic organ disease including AKI, CKD, myocarditis, and NASH. REVTx‑99b is being developed as a treatment for food allergies. REVDx‑501 is being developed as a rapid diagnostic that can be used to detect IP-10 as a surrogate biomarker for any type of respiratory infection, eliminating the need for specialized instrumentation.

For more information on Revelation, please visit

Sandra Vedrick

Vice President, Investor Relations & Human Resources

Revelation Biosciences Inc.



Chester Zygmont, III

Chief Financial Officer

Revelation Biosciences Inc.


Source: Revelation Biosciences Inc.

Revelation Biosciences Inc


REVB Rankings

REVB Latest News

REVB Stock Data

Pharmaceutical Preparation Manufacturing
Regional Banks, Finance

About REVB

we develop immunologic therapeutics and diagnostics designed to make the world a healthier place